209 related articles for article (PubMed ID: 31100307)
1. Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-mesenchymal transition in lung cancer by upregulating vimentin expression.
Jiang YN; Ni XY; Yan HQ; Shi L; Lu NN; Wang YN; Li Q; Gao FG
Exp Cell Res; 2019 Aug; 381(2):165-171. PubMed ID: 31100307
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulation.
Jiang YN; Yan HQ; Huang XB; Wang YN; Li Q; Gao FG
Oncotarget; 2015 Dec; 6(38):40719-33. PubMed ID: 26528698
[TBL] [Abstract][Full Text] [Related]
3. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.
Yan HQ; Zhang D; Shi YY; You X; Shi L; Li Q; Gao FG
Oncotarget; 2016 Sep; 7(38):62070-62083. PubMed ID: 27556690
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
[TBL] [Abstract][Full Text] [Related]
5. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.
Tian L; Shen D; Li X; Shan X; Wang X; Yan Q; Liu J
Oncotarget; 2016 Jan; 7(2):1619-32. PubMed ID: 26636541
[TBL] [Abstract][Full Text] [Related]
7. Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model.
Chakraborty S; Kumar A; Faheem MM; Katoch A; Kumar A; Jamwal VL; Nayak D; Golani A; Rasool RU; Ahmad SM; Jose J; Kumar R; Gandhi SG; Dinesh Kumar L; Goswami A
Cell Death Dis; 2019 Jun; 10(6):467. PubMed ID: 31197132
[TBL] [Abstract][Full Text] [Related]
8. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
[TBL] [Abstract][Full Text] [Related]
10. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation.
Yan HQ; Huang XB; Ke SZ; Jiang YN; Zhang YH; Wang YN; Li J; Gao FG
Cancer Sci; 2014 Sep; 105(9):1220-7. PubMed ID: 24988892
[TBL] [Abstract][Full Text] [Related]
12. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
13. BTBD7 Downregulates E-Cadherin and Promotes Epithelial-Mesenchymal Transition in Lung Cancer.
Shu J; Wang L; Han F; Chen Y; Wang S; Luo F
Biomed Res Int; 2019; 2019():5937635. PubMed ID: 31886230
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.
Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M
PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847
[TBL] [Abstract][Full Text] [Related]
15. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells.
Li L; Yan S; Zhang H; Zhang M; Huang G; Chen M
BMC Cancer; 2019 Sep; 19(1):894. PubMed ID: 31492158
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-mediated SOD-2 upregulation contributes to epithelial-mesenchymal transition and migration of tumor cells in aflatoxin G
Yi L; Shen H; Zhao M; Shao P; Liu C; Cui J; Wang J; Wang C; Guo N; Kang L; Lv P; Xing L; Zhang X
Sci Rep; 2017 Aug; 7(1):7953. PubMed ID: 28801561
[TBL] [Abstract][Full Text] [Related]
17. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: An in vivo and in vitro study.
Chen S; Zhang JQ; Chen JZ; Chen HX; Qiu FN; Yan ML; Chen YL; Peng CH; Tian YF; Wang YD
Int J Biol Macromol; 2017 Sep; 102():718-728. PubMed ID: 28344092
[TBL] [Abstract][Full Text] [Related]
18. Synthetic 8-hydroxydeoxyguanosine inhibited metastasis of pancreatic cancer through concerted inhibitions of ERM and Rho-GTPase.
Park JM; Han YM; Jeong M; Chung MH; Kwon CI; Ko KH; Hahm KB
Free Radic Biol Med; 2017 Sep; 110():151-161. PubMed ID: 28602912
[TBL] [Abstract][Full Text] [Related]
19. Rubus idaeus L Inhibits Invasion Potential of Human A549 Lung Cancer Cells by Suppression Epithelial-to-Mesenchymal Transition and Akt Pathway In Vitro and Reduces Tumor Growth In Vivo.
Chu SC; Hsieh YS; Hsu LS; Chen KS; Chiang CC; Chen PN
Integr Cancer Ther; 2014 May; 13(3):259-73. PubMed ID: 24335666
[TBL] [Abstract][Full Text] [Related]
20. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
